Registry for outcomes in KRAS G12R pancreatic cancer on MEK therapy
Part of Cancer, Digestive system clinical trials.
This study keeps a registry (a secure database) to track how people with advanced pancreatic cancer and a KRAS G12R mutation do after treatment with a MEK inhibitor–based combination. It helps doctors understand which outcomes matter most for this specific genetic type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have advanced pancreatic ductal adenocarcinoma, as your care team confirms.
- Your tumor (or cancer DNA in blood) must show the KRAS G12R mutation from an approved test.
- Be able to read and understand the informed consent form and be willing to sign it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (GDC-7035) given with other cancer treatments to see if it is safe and works in people with advanced colorectal or pancreatic cancer that has a specific genetic change called KRAS G12D.
This study tests an experimental drug called VS-7375 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth.
This Phase 1/2 study tests a lab-made immune cell (T-cell) treatment that targets a specific KRAS mutation (G12V) found in some pancreatic cancers. It may help shrink tumors or control cancer growth after standard treatment, and it mainly focuses on safety and early effectiveness.
This study collects information from patients with pancreatic cancer that has a specific genetic change called a KRAS mutation, who have already received treatment targeting this mutation. Researchers will track outcomes to better understand how these treatments work.
This trial tests a new experimental drug, RNK08954, for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can help shrink or slow the cancer.
This registry collects information about people with advanced pancreatic cancer who are receiving first-line palliative treatment. It helps doctors understand which treatment choices are used and how people do over time.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.